𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers

✍ Scribed by Eric Vuurman; Eef Theunissen; Anita van Oers; Cees van Leeuwen; Jelle Jolles

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
125 KB
Volume
22
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Introduction

Rupatadine fumarate is a potent, selective, histamine H~1~‐receptor antagonist and PAF inhibitor with demonstrated efficacy for the relief of allergic rhinitis. Rupatadine does not easily cross the blood–brain barrier and is believed to be non‐sedating at therapeutic doses. Consequently, rupatadine should show no impairment on car driving.

Objective

This study compared the acute effects of rupatadine, relative to placebo and hydroxyzine (as an active control), on healthy subjects' driving performance.

Methods

Twenty subjects received a single dose of rupatadine 10 mg, hydroxyzine 50 mg, or placebo in each period of this randomized, double‐blind, three‐way crossover study. Two hours postdosing, subjects operated a specially instrumented vehicle in tests designed to measure their driving ability. Before and after the driving tests ratings of sedation were recorded.

Results

There was no significant difference between rupatadine and placebo in the primary outcome variable: standard deviation of lateral position (SDLP); however, hydroxyzine treatment significantly increased SDLP (p < 0.001 for both comparisons). Objective (Stanford sleepiness scale) and subjective sedation ratings (Visual Analogue Scales) showed similar results: subjects reported negative effects after hydroxyzine but not after rupatadine.

Conclusion

Rupatadine 10 mg is not sedating and does not impair driving performance. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

The effects of acute treatment with tand
The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteers
✍ Masahiro Takahashi; Kunihiro Iwamoto; Yukiko Kawamura; Yukako Nakamura; Ryoko Is 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract ## Objective To assess the effects of two anxiolytics, diazepam and tandospirone, on driving performance from methodological viewpoints taking frequent rear‐end collisions into account. ## Methods In this double‐blinded, three‐way crossover trial, 18 healthy males received acute dose

Lack of interaction between amisulpride
Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers
✍ M. C. Perault; L. Bergougnan; A. Paillat; I. Zieleniuk; P. Rosenzweig; B. Vandel 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

The potential pharmacodynamic interaction between amisulpride (a benzamide-type antipsychotic) and lorazepam was evaluated in a randomized, double-blind, cross-over, placebo-controlled study involving 18 healthy caucasian male volunteers, aged 18±35 years. They received single doses of amisulpride 5

Complete bioavailability and lack of foo
Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers
✍ P. Delrat; M. Paraire; R. Jochemsen 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

## Abstract A new modified release (MR) formulation containing 30 mg of gliclazide was developed to obtain a better predictable release of the active principle and to allow once‐daily dosing regimen. An absolute bioavailability study was carried out to characterise the performance of the new formul

Effects of nocturnal doses of mirtazapin
Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers
✍ J. G. Ramaekers; N. D. Muntjewerff; L. M. A. Van Veggel; M. M. C. Uiterwijk; J. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

Eighteen healthy volunteers participated in a randomized, double blind, cross-over trial. They received mirtazapine, mianserin or placebo during separate periods of 15 days. Mirtazapine and mianserin were respectively administered in doses of 15 mg and 30 mg nocte for the ®rst 7 days and doses of 30

The effects of acute treatment with paro
The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: A double-blind crossover trial
✍ Kunihiro Iwamoto; Masahiro Takahashi; Yukako Nakamura; Yukiko Kawamura; Ryoko Is 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

## Abstract ## Objective To assess the effects of antidepressants on driving performance from a different methodological viewpoint in light of the recent traffic accidents. ## Methods In this double‐blinded, 3‐way crossover trial, 17 healthy males received acute doses of 10 mg paroxetine, 25 mg